By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Madrigal Pharmaceuticals 

500 Office Center Drive
Suite 400
Fort Washington  Pennsylvania  19034  U.S.A.
Phone: 267-327-4445 Fax:


SEARCH JOBS


Industry
Pharmaceutical






Company News
Madrigal Announces Positive Outcome From Pre-Planned DSMB Safety Review And Completion Of Enrollment Of Phase II Study Of MGL-3196 In Patients With Heterozygous Familial Hypercholesterolemia 9/19/2017 7:37:45 AM
Madrigal Reports 2017 Second Quarter Financial Results 8/10/2017 12:25:16 PM
Madrigal Completes Enrollment In Phase II Proof-Of-Concept Study With MGL-3196 For Treatment Of NASH 8/1/2017 11:58:40 AM
Madrigal Announces $35 Million Private Placement Offering 6/21/2017 7:43:31 AM
Madrigal Reports 2017 First Quarter Financial Results 5/12/2017 9:55:47 AM
Madrigal Reports 2016 Fourth Quarter And Year-End Financial Results, Reviews Key Corporate Achievements And Provides Update On Lead Clinical-Stage Compound, MGL-3196 4/3/2017 7:38:48 AM
Madrigal Announces The Initiation Of A Phase II Study Of MGL-3196 In Patients With Heterozygous Familial Hypercholesterolemia (HeFH) 2/23/2017 8:48:38 AM
Madrigal Reports Third Quarter 2016 Financial Results 11/15/2016 10:45:06 AM
Madrigal Announces The Initiation Of A Phase 2 Study Of MGL-3196 In Patients With Non-Alcoholic Steatohepatitis (NASH) 10/20/2016 12:15:30 PM
Madrigal Announces The Initiation Of A Phase II Study Of MGL-3196 In Patients With Non-Alcoholic Steatohepatitis (NASH) 10/20/2016 8:13:19 AM
12
//-->